Evidence map›Paper›PMID 24726300›Full record

ArticleInternational journal of pharmaceutics2014

Preliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas.

Alexandra Gaubert, Tina Kauss, Mathieu Marchivie, Boubakar B Ba, Martine Lembege, Fawaz Fawaz, Jean-Michel Boiron, Xavier Lafarge, Niklas Lindegardh, Jean-Louis Fabre and 5 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 5 countries.

Alexandra GaubertUniversité de Bordeaux, EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Bordeaux, France.
Tina KaussUniversité de Bordeaux, EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Bordeaux, France. Electronic address: tina.kauss@u-bordeaux.fr.
Mathieu MarchivieUniversité de Bordeaux, FRE 3396 CNRS Pharmacochimie, Bordeaux, France.
Boubakar B BaUniversité de Bordeaux, EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Bordeaux, France.
Martine LembegeUniversité de Bordeaux, Laboratory of Organic and Therapeutic Chemistry, Pharmacochimie, Bordeaux, France.
Fawaz FawazUniversité de Bordeaux, EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Bordeaux, France.
Jean-Michel BoironEFS (Etablissement Français du Sang) Aquitaine Limousin, Bordeaux, France.
Xavier LafargeEFS (Etablissement Français du Sang) Aquitaine Limousin, Bordeaux, France.
Niklas LindegardhFaculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Jean-Louis FabreOTECI (Office Technique d'Etude et de Coopération Internationale), Paris, France.
Nicholas J WhiteFaculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, UK.
Piero L OlliaroCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, UK; UNICEF/UNDP/WB/WHO Special Program for Research & Training in Tropical Diseases (TDR), Geneva, Switzerland.
Pascal MilletUniversité de Bordeaux, EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Bordeaux, France.
Luc Grislain
Karen GaudinUniversité de Bordeaux, EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Bordeaux, France.
Université de Bordeaux · FRÉtablissement Français du Sang · FRMahidol University · THAngkor Hospital for Children · KHCentre National de la Recherche Scientifique · FR

Funding

Wellcome Trust 085242/Z/08/ZWellcome Trust 093956World Health Organization 001
6 · The paper itself

Abstract

Artemether (AM) plus azithromycin (AZ) rectal co-formulations were studied to provide pre-referral treatment for children with severe febrile illnesses in malaria-endemic areas. The target profile required that such product should be cheap, easy to administer by non-medically qualified persons, rapidly effective against both malaria and bacterial infections. Analytical and pharmacotechnical development, followed by in vitro and in vivo evaluation, were conducted for various AMAZ coformulations. Of the formulations tested, stability was highest for dry solid forms and bioavailability for hard gelatin capsules; AM release from AMAZ rectodispersible tablet was suboptimal due to a modification of its micro-crystalline structure.

Indexed as

Endemic DiseasesAdministration, RectalAge FactorsAnimalsAnti-Bacterial AgentsAntimalarialsArtemetherArtemisininsAzithromycinBiological AvailabilityCapsulesChemistry, PharmaceuticalCrystallizationCrystallography, X-RayDrug CombinationsExcipientsAnti-Bacterial AgentsAntimalarialsArtemetherArtemisininsAzithromycinCapsulesDrug CombinationsExcipientsTabletsAcute respiratory infectionsArtemetherAzithromycinMalariaPediatricRectal route

Identifiers

PMID24726300
PMCPMC4045394
OpenAlexW2019242842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.